A look inside the factory in Kundl, Austria, where Sandoz, a unit of Novartis, makes biosimilar drugs.
Mark McCamish spent more than five years preparing for a presentation he gave this winter.
McCamish is in charge of biopharmaceutical drug development at the Sandoz division of Switzerland’s Novartis. He and his colleagues made the case to a panel of 14 cancer specialists and a group of Food and Drug Administration regulators that a company drug codenamed EP2006 should be approved for sale in the U.S.
The drug, brand name Zarxio, is similar to but not quite identical to Amgen’s Neupogen, a medicine approved by the FDA back in 1991 to fight infections in cancer patients.
Industry representatives, patient advocates and
Tagged: obamacare news